Hanson & Doremus Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Hanson & Doremus Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5	Closed	–	–	522
2018 Q1	$0	Hold	5	–	–	﹤0.01%	514
2017 Q4	$1K	Hold	5	–	–	﹤0.01%	492
2017 Q3	$0	Hold	5	–	–	﹤0.01%	504
2017 Q2	$0	Hold	5	–	–	﹤0.01%	501
2017 Q1	$1K	Hold	5	–	–	﹤0.01%	469
2016 Q4	$601	Hold	5	–	–	﹤0.01%	453
2016 Q3	$1K	Hold	5	–	–	﹤0.01%	440
2016 Q2	$1K	Hold	5	–	–	﹤0.01%	438
2016 Q1	$1K	Hold	5	–	–	﹤0.01%	452
2015 Q4	$1K	Hold	5	–	–	﹤0.01%	462
2015 Q3	$1K	Hold	5	–	–	﹤0.01%	447
2015 Q2	$3K	Hold	5	–	–	﹤0.01%	428
2015 Q1	$2K	Buy	+5	New	+$2.52K	﹤0.01%	447

Other funds holding VIRX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Hanson & Doremus Investment Management's VIRX Position: Q2 2018 in Review

Hanson & Doremus Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2018, closing a stake of 5 shares.

Hanson & Doremus Investment Management first reported a position in VIRX in Q1 2015 and held it in 13 quarters. The position peaked at $3K in Q2 2015. 50 funds tracked by Wall St. Rank hold VIRX as of Q2 2018.

Hanson & Doremus Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Hanson & Doremus Investment Management sold 5 Viracta Therapeutics, Inc. Common Stock shares in Q2 2018.
Hanson & Doremus Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 13 quarters.
Hanson & Doremus Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $3K in Q2 2015.
50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2018, filed 8 Aug 2018.